<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="activity in the central nervous system (CNS) cells compared to" exact="sofosbuvir" post="(Bugert-MBDC-2018-GO3), novel protease inhibitors for Zika virus as surrogate"/>
 <result pre="detail elsewhere [133]. Further candidate anti-poxvirus drugs include kinase inhibitors" exact="imatinib" post="(Gleevec/STI-571; [122, 123]) and olomoucine [61], terameprocol [119], mitoxandrone"/>
 <result pre="these two Mabs for all further treatments [150]. Remdesivir (GS-5734;1-cyano-substituted" exact="adenosine" post="nucleotide analogue), a nucleoside-analogue prodrug and lead compound of"/>
 <result pre="shown the efficacy of favipiravir [13, 14]). While extensively tested," exact="ribavirin" post="is not FDA approved for EBOV [65]. Other promising"/>
 <result pre="alleviating peripheral symptoms but not providing cure [1, 3]. Intranasal" exact="ribavirin" post="may be more effective. Ribavirin resolves joint swelling in"/>
 <result pre="FDA approval is pending [49]. An in vitro comparison between" exact="ribavirin" post="and favipiravir revealed that efficacy is cell-type dependent [45]."/>
 <result pre="[141]. Compounds with known cellular targets include the cancer drugs" exact="mefenamic acid" post="and sorafenib, inhibiting replication of CHIKV and other alphaviruses"/>
 <result pre="clinical trials were unable to show significant beneficial effects of" exact="ribavirin" post="versus CCHFV [70, 78]. Further interesting candidates for virus-specific"/>
 <result pre="by the FDA (Table 1), the most promising candidate is" exact="sofosbuvir" post="[18]. Sofosbuvir was initially developed and approved by FDA"/>
 <result pre="of influenza B viruses [42]. Anti-orthomyxovirus drugs. FDA-approved neuraminidase inhibitors" exact="oseltamivir" post="(Tamiflu®), zanamivir (Relenza®), laninamivir (Inavir®), and peramivir have marginal"/>
 <result pre="B viruses [42]. Anti-orthomyxovirus drugs. FDA-approved neuraminidase inhibitors oseltamivir (Tamiflu®)," exact="zanamivir" post="(Relenza®), laninamivir (Inavir®), and peramivir have marginal clinical benefits"/>
 <result pre="FDA-approved neuraminidase inhibitors oseltamivir (Tamiflu®), zanamivir (Relenza®), laninamivir (Inavir®), and" exact="peramivir" post="have marginal clinical benefits only when given early but"/>
 <result pre="the polymerase PA-PB1 subunits of influenza virus [106]. Alicyclic amines/aminoadamantanes" exact="amantadine" post="and rimantadine, first described in 1985 as M2 protein"/>
 <result pre="Cochrane review found no evidence for efficacy or safety of" exact="amantadine" post="for the treatment of influenza A [6]. However, their"/>
 <result pre="combinations of antiviral compounds with similar or different MoA are" exact="ribavirin" post="with vitamin A in measles infections [12], ribavirin with"/>
 <result pre="MoA are ribavirin with vitamin A in measles infections [12]," exact="ribavirin" post="with favipiravir in Zika virus infections [75], and ribavirin"/>
 <result pre="[12], ribavirin with favipiravir in Zika virus infections [75], and" exact="ribavirin" post="with mefenamic acid in infections with Chikungunya virus [126]."/>
 <result pre="with favipiravir in Zika virus infections [75], and ribavirin with" exact="mefenamic acid" post="in infections with Chikungunya virus [126]. Antiviral drug combinations"/>
 <result pre="viruses in mice [134]. Previously thought as a one-family-broad-spectrum compound," exact="sofosbuvir" post="(Sovaldi™, Soforal™) has in vitro and in vivo activity"/>
 <result pre="in extracts [27]. Treatment of viral hemorrhagic fevers (VHF) with" exact="ribavirin" post="Viral hemorrhagic fevers (VHFs) cause the highest mortality in"/>
 <result pre="VHF and is used under compassionate use protocols only. Intravenous" exact="ribavirin" post="reduces mortality of HFRS if combined with hemodialysis and"/>
 <result pre="bunyaviruses (HFRS, Crimean-Congo fever, and Rift Valley fever). However, intravenous" exact="ribavirin" post="does not show any benefits for the treatment of"/>
 <result pre="by mitoxantroneAntivir Res20129330530810.1016/j.antiviral.2011.12.00122182595 6.Alves GalvãoMGRocha Crispino SantosMAAlves da CunhaAJAmantadine and" exact="rimantadine" post="for influenza A in children and the elderlyCochrane Database"/>
 <result pre="616 antiviral activity against chikungunya virusAntivir Res201398121810.1016/j.antiviral.2013.01.00223380636 10.BazMCarbonneauJRhéaumeCCavanaghM-HBoivinGCombination therapy with" exact="oseltamivir" post="and favipiravir delays mortality but does not prevent oseltamivir"/>
 <result pre="with oseltamivir and favipiravir delays mortality but does not prevent" exact="oseltamivir" post="resistance in immunodeficient mice infected with pandemic A(H1N1) Influenza"/>
 <result pre="BeinekeABaumgärtnerWWohlseinPCross-species transmission of canine distemper virus—an updateOne Health20151495910.1016/j.onehlt.2015.09.00228616465 12.BichonAAubryCBenarousLDrouetHZandottiCParolaPLagierJ-CCase report:" exact="ribavirin" post="and vitamin A in a severe case of measlesMedicine"/>
 <result pre="hazards in the Kosovo warNephrol Dial Transpl1999141843184410.1093/ndt/14.8.1843 18.Bullard-FeibelmanKMGoveroJZhuZSalazarVVeselinovicMDiamondMSGeissBJThe FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntivir Res201713713414010.1016/j.antiviral.2016.11.02327902933 19.CallawayE‘Make Ebola a thing"/>
 <result pre="CDCGlobal measles mortality, 2000–2008MMWR2009581321132619959985 23.ChanJF-WChikKK-HYuanSYipCC-YZhuZTeeK-MTsangJO-LChanCC-SPoonVK-MLuGZhangAJLaiK-KChanK-HKaoRY-TYuenK-YNovel antiviral activity and mechanism of" exact="bromocriptine" post="as a Zika virus NS2B-NS3 protease inhibitorAntivir Res.2017141293710.1016/j.antiviral.2017.02.00228185815 24.ChanJF-WZhuZChuHYuanSChikKK-HChanCC-SPoonVK-MYipCC-YZhangXTsangJO-LZouZTeeK-MShuaiHLuGYuenK-YThe"/>
 <result pre="bromocriptine as a Zika virus NS2B-NS3 protease inhibitorAntivir Res.2017141293710.1016/j.antiviral.2017.02.00228185815 24.ChanJF-WZhuZChuHYuanSChikKK-HChanCC-SPoonVK-MYipCC-YZhangXTsangJO-LZouZTeeK-MShuaiHLuGYuenK-YThe" exact="celecoxib" post="derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via"/>
 <result pre="yearsClin Microbiol Rev20162969574710.1128/CMR.00102-1527281742 33.de FreitasCSHigaLMSacramentoCQFerreiraACReisPADelvecchioRMonteiroFLBarbosa-LimaGJames-WestgarthHVieiraYRMattosMRochaNHoelzLVBLemeRPPBastosMMRodriguesGOLLopesCEMQueiroz-JuniorCMLimaCXCostaVVTeixeiraMMBozzaFABozzaPTBoechatNTanuriASouzaTMLYellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Negl Trop Dis.201913707210.1371/journal.pntd.0007072"/>
 <result pre="Epidemiological Report for 2016. https://www.ecdc.europa.eu/en/publications-data/hantavirus-infection-annual-epidemiological-report-2016 39.EyerLZouharováDŠirmarováJFojtíkováMŠtefánikMHaviernikJNenckaRde ClercqERůžekDAntiviral activity of the" exact="adenosine" post="analogue BCX4430 against West Nile virus and tick-borne flavivirusesAntivir"/>
 <result pre="weapons-a primer for microbiologistsAnnu Rev Microbiol20015523525310.1146/annurev.micro.55.1.23511544355 59.HawmanDWHaddockEMeade-WhiteKWilliamsonBHanleyPWRosenkeKKomenoTFurutaYGowenBBFeldmannHFavipiravir (T-705) but not" exact="ribavirin" post="is effective against two distinct strains of Crimean-Congo hemorrhagic"/>
 <result pre="and control strategy in admitted patientsCasp J Intern Med20123443444 69.JeulinHVenardVCarapitoDFinanceCKedzierewiczFEffective" exact="ribavirin" post="concentration in mice brain using cyclodextrin as a drug"/>
 <result pre="protein against a small-molecule membrane fusion inhibitorVirus Res2019259283710.1016/j.virusres.2018.10.00330296457 75.KimJ-ASeongR-KKumarMShinOSFavipiravir and" exact="ribavirin" post="inhibit replication of Asian and African strains of Zika"/>
 <result pre="drug screening in primary human cellsAntivir Res2018150202910.1016/j.antiviral.2017.12.00529224735 78.KoksalIYilmazGAksoyFAydinHYavuzIIskenderSAkcayKErensoySCaylanRAydinKThe efficacy of" exact="ribavirin" post="in the treatment of Crimean-Congo hemorrhagic fever in Eastern"/>
 <result pre="89.LubySPThe pandemic potential of Nipah virusAntivir Res2013100384310.1016/j.antiviral.2013.07.01123911335 90.LundbergLBrahmsAHooperICareyBLinS-CDahalBNarayananAKehn-HallKRepurposed FDA-Approved drug" exact="sorafenib" post="reduces replication of Venezuelan equine encephalitis virus and other"/>
 <result pre="Lassa virus antiviral targets an arenavirus virulence determinantPLoS Pathog201814e100743910.1371/journal.ppat.100743930576397 92.MalinoskiFJHastySEUsseryMADalrympleJMProphylactic" exact="ribavirin" post="treatment of dengue type 1 infection in rhesus monkeysAntivir"/>
 <result pre="virus serotypes in AG129 mouse models: proof-of-concept studies with the" exact="adenosine" post="nucleoside inhibitor NITD-008Antivir Res201815410410910.1016/j.antiviral.2018.04.01229665374 102.MohrELMcMullanLKLoMKSpenglerJRBergeronÉAlbariñoCGShrivastava-RanjanPChiangC-FNicholSTSpiropoulouCFFlintMInhibitors of cellular kinases with"/>
 <result pre="virus (smallpox)Antimicrob Agents Chemother201357126246625310.1128/aac.00977-1324100494 105.MumtazNJimmersonLCBushmanLRKiserJJAronGReuskenCBEMKoopmansMPGvan KampenJJACell-line dependent antiviral activity of" exact="sofosbuvir" post="against Zika virusAntivir Res.201714616116310.1016/j.antiviral.2017.09.00428912011 106.NannettiGMassariSMercorelliBBertagninCDesantisJPalùGTabarriniOLoregianAPotent and broad-spectrum cycloheptathiophene-3-carboxamide compounds"/>
 <result pre="biological and chemical (NBC) defensive operations—part II 108.NelsonDRet al.Balapiravir plus" exact="peginterferon alfa-2a" post="(40KD)/ribavirin in a randomized trial of hepatitis C genotype"/>
 <result pre="of GTP pool is not the predominant mechanism by which" exact="ribavirin" post="exerts its antiviral effect on Lassa virusAntivir Res201191899310.1016/j.antiviral.2011.05.00621616094 113.OoARausaluKMeritsAHiggsSVanlandinghamDBakarSAZandiKDeciphering"/>
 <result pre="116.ParkerSTouchetteEOberleCAlmondMRobertsonATrostLCLampertBPainterGBullerRMEfficacy of therapeutic intervention with an oral ether-lipid analogue of" exact="cidofovir" post="(CMX001) in a lethal mousepox modelAntivir Res.200877394910.1016/j.antiviral.2007.08.00317904231 117.PetersenEKanteleAKoopmansMAsogunDYinka-OgunleyeAIhekweazuCZumlaAHuman monkeypox:"/>
 <result pre="infection in macaquesEmerg Infect Dis2018241696169910.3201/eid2409.18023329882740 126.RothanHABahraniHAbdulrahmanAYMohamedZTeohTCOthmanSRashidNNRahmanNAYusofRMefenamic acid in combination with" exact="ribavirin" post="shows significant effects in reducing chikungunya virus infection In"/>
 <result pre="members of the family BunyaviridaeVirus Adapt Treat2010292010.2147/VAAT.S6903 136.TaylorRKotianPWarrenTPanchalRBavariSJulanderJDoboSRoseAEl-KattanYTaubenheimBBabuYSheridanWPBCX4430—a broad-spectrum antiviral" exact="adenosine" post="nucleoside analog under development for the treatment of Ebola"/>
 <result pre="Afr Med J Suid-Afr Tydskr Vir Geneeskd198568718721 141.VargheseFSKaukinenPGläskerSBespalovMHanskiLWennerbergKKümmererBMAholaTDiscovery of berberine," exact="abamectin" post="and ivermectin as antivirals against chikungunya and other alphavirusesAntivir"/>
 <result pre="J Suid-Afr Tydskr Vir Geneeskd198568718721 141.VargheseFSKaukinenPGläskerSBespalovMHanskiLWennerbergKKümmererBMAholaTDiscovery of berberine, abamectin and" exact="ivermectin" post="as antivirals against chikungunya and other alphavirusesAntivir Res201612611712410.1016/j.antiviral.2015.12.01226752081 142.WaltonTEJohnsonKMMonathTPVenezuelan"/>
</results>
